Alumis Inc. · NASDAQ:ALMS
Alumis — Corporate Update (January 2026)
25 slides from Alumis's corporate update, Jan 6, 2026
Slide 1: Envudeucitinib ONWARD1 and ONWARD2 Phase 3 Topline Readout
1 Envudeucitinib ONWARD1 and ONWARD2 Phase 3 Topline Readout Analyst and Investor Webcast – January 6, 2026
Slide 2: Forward-Looking Statements
2 Forward - Looking Statements This presentation contains forward looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 . Such statements are based upon current plans, estimates and expectation
Slide 3: Agenda
3 Agenda Speaker Topic John Schroer, CFO Welcome Martin Babler, CEO Opening Remarks Jörn Drappa , MD, PhD, CMO ONWARD Phase 3 Data Review Martin Babler, CEO Psoriasis Opportunity All Q&A
Slide 4: Overview
alumis Overview alumis
Slide 5: ONWARD1 and ONWARD2 Met All Primary and Secondary Endpoints
5 • Leading skin clearance for oral plaque psoriasis therapies • We believe envudeucitinib profile is highly compelling to physicians and patients • The placebo - adjusted response rates for the co - primary endpoints were consistent between the two trials • Phase 3 efficacy exceeded Phase 2 program
Slide 6: Alumis' Next-Gen TYK2 Inhibitors: Two Pipelines-in-a-Pill
6 Alumis ' Next - Gen TYK2 Inhibitors: Two Pipelines - in - a - Pill 1 and 2: 2032 market projections; Source: Evaluate Pharma, January 2026 Significant market opportunity (projected $ 180B+ 2 ) across many indications with potential to be addressed by TYK2 molecules. Envudeucitinib and A - 005 prov
Slide 7: Unlocking TYK2i Full Therapeutic Potential
7 Hypothesis demonstrated: maximal target engagement translates into higher clinical efficacy * IC90 maintained for >24 hours at clinically tested doses (STRIDE study; 40 mg BID dosing) Positioned to Unlock the Full Potential of TYK2i Mechanism Human Genetics : TYK2 loss - of - function variants pro
Slide 8: 2026 is Expected to be a Breakout Year for Envudeucitinib
8 ONWARD1 & 2 met all primary and secondary endpoints Maximal IL - 23/IL - 17 pathway inhibition clinically demonstrated in psoriasis Phase 3 data presentation Additional long - term psoriasis data expected 2H 2026 Anticipated NDA filing 2H 2026 Phase 2b LUMUS SLE topline results expected Q3 2026 De
Slide 9: Envudeucitinib ONWARD1 and ONWARD2 Phase 3 Topline Data
9 Envudeucitinib ONWARD1 and ONWARD2 Phase 3 Topline Data
Slide 10: Phase 3 Psoriasis Clinical Program: Well-Designed and Rapidly Executed
10 Phase 3 Psoriasis Clinical Program: Well - Designed and Rapidly Executed Two Phase 3 trials and LTE to evaluate efficacy & safety of envudeucitinib in moderate - to - severe plaque psoriasis Envudeucitinib , 40mg BID (N=420) Treatment Period Maintenance Placebo (N= 210 ) Wk 16 : Rollover to envud
Slide 11: All Primary and Secondary Endpoints Met with High Statistical Significance
11 • Both trials met all primary and secondary endpoints with high statistical significance • Skin clearance deepened through Week 24 • Rapid onset of action, with clear PASI 90 separation from placebo as early as Week 4 • Clinically meaningful improvements in patient reported outcomes related to Qu
Slide 12: Envudeucitinib Delivered a Favorable Safety Profile
12 ONWARD1 and ONWARD2 topline data Envudeucitinib Delivered a Favorable Safety Profile • Generally well tolerated through Week 24 in both ONWARD1 and ONWARD2 and consistent with Alumis ’ Phase 2 program, including the Phase 2 open - label extension • No new safety signal observed in Phase 3 • Treat
Slide 13: ONWARD: a Global Phase 3 Development Program
13 1700+ patients enrolled at >270 study sites in 10 months ONWARD: a Global Phase 3 Development Program All ONWARD1 & 2 sites participating in ONWARD3 long - term extension study (ESK - 001 - 016) Canada Belgium Bulgaria Australia Portugal Japan Germany Czech Republic United States South Korea Pola
Slide 14: ONWARD1 and ONWARD2: Key Inclusion and Exclusion Criteria
14 ONWARD1 and ONWARD2: Key Inclusion and Exclusion Criteria • Males or females, age ≥18 years at the Screening Visit • Total body weight >40 kg (88 lb ) • Diagnosis of plaque psoriasis for ≥6 months prior to the Screening Visit • Plaques covering ≥10% of BSA at Screening and Day 1 • PASI ≥12 at Scr
Slide 15: Demographics and Baseline Characteristics for ONWARD1 and ONWARD2
15 Balanced patients and disease characteristics across groups Data based on average from both studies Demographics and Baseline Characteristics for ONWARD1 and ONWARD2 • 64 - 67% Male • 79 - 89% White • 33 - 38% United States, • 6.1% (56 patients) enrolled from Japan in ESK - 001 - 016 study only •
Slide 16: We Expect to Share Additional Data at Future Medical Conferences
16 We Expect to Share Additional Data at Future Medical Conferences Efficacy • PASI 75 at week 24 • PASI 90 at week 24 • PASI 100 at week 24 • sPGA at week 24 Patient Reported Outcomes • PSSD at week 24 • DLQI at week 24 • NRS at week 24 • %BSA at week 24 Special Area Involvement • Scalp • Hands and
Slide 17: Key Competitor Efficacy Comparison
17 Key Competitor Efficacy Comparison Envudeucitinib PASI 75, 90 and 100 response rates similar to or greater than icotrokinra PASI rates PASI 100 Week 24 PASI 90 Week 24 PASI 75 Week 16 >40% 74% 65% Ico ADVANCE 1 Ico ADVANCE 2 Sotyktu Envudeucitinib Envudeucitinib data are presented as an average a
Slide 18: Envudeucitinib Substantial Market Potential in Psoriasis
18 Envudeucitinib Substantial Market Potential in Psoriasis
Slide 19: Many patients remain untreated or undertreated, despite available treatments
19 Many patients remain untreated or undertreated, despite available treatments 1. National Psoriasis Foundation. Psoriasis Statistics. Available at: https:// www.psoriasis.org /content/statistics. Accessed December 2025. 2. IQVIA Analysis, Stable and eligible newly diagnosed patients from April 202
Slide 20: Multiple Entry Points Available in Growing Psoriasis Market
20 High - efficacy orals well - positioned to capture market share in $40B projected market by 2030 1 1. Source: Evaluate Pharma as of December 2025. 2. Source: Veeva Claims data from 1/1/2025 to 6/30/25. Oral: apremilast, deucravacitinib ; TNF: certolizumab, etanercept, Infliximab; IL - 17: ixekizu
Slide 21: Key Drivers of Use in Psoriasis Treatment
21 Key Drivers of Use in Psoriasis Treatment 1. In Industry surveys: J&J Business Review Dec 2023 (survey of n=395 patients with moderate - to - severe psoriasis). 2. Internal company market research I’m tired. Tired of the itching, the burning, the flaking - tired of how you (psoriasis) make me fee
Slide 22: Envudeucitinib Profile is Highly Compelling to Physicians and Patients
22 1. Internal company market research Envudeucitinib Profile is Highly Compelling to Physicians and Patients Market Need Envudeucitinib • Leading skin clearance responses for next generation oral therapies • Rapid onset of action: Clear separation from placebo as early as Week 4 for PASI 90 • Impro
Slide 23: Two Pipeline-in-a-Pill Opportunities; $180B+ Potential Total Market
23 Neurology: $44B Rheumatology: $38B Gastroenterology: $41B Dermatology: $49B Other Indications: $9B Multiple Sclerosis Parkinson's Disease Alzheimer's Disease Systemic Lupus Erythematosus Psoriatic Arthritis Sarcoidosis Sjogren’s Disease Rheumatoid Arthritis Juvenile Idiopathic Arthritis Ul
Slide 24: Late-stage Pipeline with Multiple Near-term Anticipated Milestones
24 Late - stage Pipeline with Multiple Near - term Anticipated Milestones * Development program evaluation ongoing Our pathway to patients Anticipated Milestones Phase 3 Phase 2 Phase 1 Preclinical Indication Program TYK2i 1H’26: Phase 3 data presentation 2H’26: NDA filing 2H’26 : Phase 2 two - year
Slide 25: Thank You!
alumis Thank You! alumis 25